Published in Eur J Med Res on April 08, 2010
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis (2011) 1.04
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97
Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene. Eur J Med Res (2011) 0.88
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol (2003) 9.19
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (2008) 4.53
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol (1997) 4.08
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology (2007) 2.39
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med (1984) 1.85
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol (2002) 1.44
Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol (2008) 1.38
Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat (2008) 1.20
Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol (1996) 1.10
Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med (2006) 1.09
Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat (2003) 0.97
Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis (1995) 0.96
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology (2007) 0.92
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther (2006) 0.91
Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol (2006) 0.90
Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int (2007) 0.85
There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV. Braz J Med Biol Res (2007) 0.85
Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Clin Infect Dis (2006) 0.84
The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood (2001) 0.83
Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis. Gastroenterol Clin Biol (2007) 0.77
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med (1988) 5.53
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology (2002) 3.96
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS (1997) 2.82
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology (2010) 2.78
Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med (1986) 2.76
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol (2002) 2.54
HIV and hepatitis C virus co-infection. Lancet Infect Dis (2004) 2.35
A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut (1997) 2.32
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol (1989) 2.09
Intrahepatic IL-8 producing Foxp3⁺CD4⁺ regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol (2013) 2.03
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Clostridium difficile infection in patients with neutropenia. Clin Infect Dis (2001) 2.00
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Acute hepatitis A in haemophiliacs. Lancet (1992) 1.96
Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. Support Care Cancer (2002) 1.95
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost (2011) 1.73
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost (2007) 1.72
Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology (1992) 1.70
Dormia baskets impacted in the bile duct: release by extracorporeal shock-wave lithotripsy. Endoscopy (1995) 1.70
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest (1999) 1.68
Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut (2008) 1.68
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Comparison of capsule endoscopy and magnetic resonance imaging for the detection of polyps of the small intestine in patients with familial adenomatous polyposis or with Peutz-Jeghers' syndrome. Endoscopy (2004) 1.64
Gallstones: pathogenesis. Lancet (1991) 1.64
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol (2002) 1.60
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology (2012) 1.60
Gallstone recurrence after shock-wave therapy. Gastroenterology (1994) 1.59
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: soluble pronucleating proteins in gallbladder and hepatic biles. J Hepatol (2001) 1.55
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Characterization of duplication breakpoints in the factor VIII gene. J Thromb Haemost (2010) 1.52
Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy (2002) 1.51
Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods (2005) 1.51
Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem (2001) 1.50
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion (2003) 1.48
Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology (1991) 1.47
Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol (2001) 1.47
Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS (2003) 1.47
Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol (2000) 1.46
[Symptoms, tumor stage and primary treatment in patients with colorectal carcinoma]. Dtsch Med Wochenschr (1997) 1.46
Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion (2010) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Surgical intervention following fragmentation of gallstones by extracorporeal shock waves. World J Surg (1989) 1.42
[Fecal incontinence]. Internist (Berl) (2000) 1.42
Serum bile acids: physiology and clinical relevance. Eur J Gastroenterol Hepatol (1995) 1.41
In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia (2013) 1.40
Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost (1994) 1.40
[Lipid metabolism disorders in pregnancy]. Dtsch Med Wochenschr (2008) 1.39
[Severe refractory pulmonary hypertension after liver transplantation for hepatitis C liver cirrhosis]. Z Gastroenterol (2006) 1.39
[The therapy of the hepatorenal syndrome in liver cirrhosis]. Dtsch Med Wochenschr (1999) 1.39
[Therapy-refractory thrombocytopenia in chronic hepatitis C]. Z Gastroenterol (2000) 1.39
[Treatment options for vascular ectasias of the gastric antrum (watermelon stomach)]. Dtsch Med Wochenschr (2001) 1.38
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother (1999) 1.33
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology (2001) 1.32
Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis. Lancet (1995) 1.32
A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther (2001) 1.28
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol (2000) 1.28
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol (1995) 1.27
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 1.25
The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med (1991) 1.23
Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 1.23
Phenotypic characterization of lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice. Pathophysiology Of biliary lipid secretion. J Lipid Res (1999) 1.22
Search for intrafamilial transmission of hepatitis C virus in hemophilia patients. Blood (1993) 1.22
Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (2001) 1.21
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol (2004) 1.20
Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol (1999) 1.20
Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant (2005) 1.20
A retrospective analysis of 3 year's experience of an interdisciplinary approach to gallstone disease including shock-waves. Ann Surg (1988) 1.19
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (1992) 1.19
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
Shock-wave therapy of gastric outlet syndrome caused by a gallstone. Gastroenterology (1989) 1.19
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology (2010) 1.18
Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1996) 1.16
HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther (2005) 1.16
Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy (2009) 1.16